Michelle W. Wu

Michelle W. Wu

Auto-generated profile, based on publicly available information

Michelle W. Wu

Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ICIvy X. Chen
Ivy X. Chen
VCVikash P. Chauhan
Vikash P. Chauhan
JPJessica Posada
Jessica Posada
MNMei R. Ng
Mei R. Ng
MWMichelle W. Wu
Michelle W. Wu
RJRakesh K. Jain
Rakesh K. Jain
Metastatic breast cancers (mBCs) are largely resistant to immune checkpoint blockade, but the mechanisms remain unclear. Primary breast cancers are characterized by a dense fibrotic stroma, which is considered immunosuppressive in multiple malignancies, but the stromal composition of breast cancer metastases and its role in immunosuppression are largely unknown. Here we show that liver and lung metastases of human breast cancers tend to be highly fibrotic, and unlike primary breast tumors, they exclude cytotoxic T lymphocytes (CTLs). Unbiased analysis of the The Cancer Genome Atlas database of human breast tumors revealed a set of genes that are associated with stromal T-lymphocyte exclusion. Among these, we focused on CXCL12 as a relevant target based on its known roles in immunosuppression in other cancer types. We found that the CXCL12 receptor CXCR4 is highly expressed in both human primary tumors and metastases. To gain insight into the role of the CXCL12/CXCR4 axis, we inhibited CXCR4 signaling pharmacologically and found that plerixafor decreases fibrosis, alleviates solid stress, decompresses blood vessels, increases CTL infiltration, and decreases immunosuppression in murine mBC models. By deleting CXCR4 in αSMA+ cells, we confirmed that these immunosuppressive effects are dependent on CXCR4 signaling in αSMA+ cells, which include cancer-associated fibroblasts as well as other cells such as pericytes. Accordingly, CXCR4 inhibition more than doubles the response to immune checkpoint blockers in mice bearing mBCs. These findings demonstrate that CXCL12/CXCR4-mediated desmoplasia in mBC promotes immunosuppression and is a potential target for overcoming therapeutic resistance to immune checkpoint blockade in mBC patients. Significance Although immune checkpoint blockade (ICB) along with nab-paclitaxel has increased progression-free survival in triple-negative breast cancer patients, a large fraction of metastatic breast cancer (mBC) patients do not benefit from ICBs. The presence of a fibrotic tumor microenvironment can suppress the immune response to cancer. Here we found fibrosis and immunosuppression in both primary and metastatic breast cancer lesions. We show that targeting CXCR4/CXCL12 signaling, using plerixafor, an Food and Drug Administration-approved drug, reduces fibrosis, alleviates immunosuppression, and significantly enhances the efficacy of immune checkpoint blockers in preclinical models of mBC. Our findings provide a deeper understanding of mechanisms by which desmoplasia promotes immunosuppression in mBC and suggest a clinically translatable approach that can be combined with immunotherapy in patients to enhance therapeutic response.

22 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
PWPutianqi Wang
Putianqi Wang
KLKen H. Loh
Ken H. Loh
MWMichelle Wu
Michelle Wu
DMDonald A. Morgan
Donald A. Morgan
MSMarc Schneeberger
Marc Schneeberger
JFJeffrey Friedman
Jeffrey Friedman

30 April 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
VCVikash P. Chauhan
Vikash P. Chauhan
ICIvy X. Chen
Ivy X. Chen
RTRong Tong
Rong Tong
MNMei Rosa Ng
Mei Rosa Ng
JMJohn D. Martin
John D. Martin
RJRakesh K. Jain
Rakesh K. Jain
Cancer-associated fibroblasts (CAFs) can either suppress or support T lymphocyte activity, suggesting that CAFs may be reprogrammable to an immunosupportive state. Angiotensin receptor blockers (ARBs) convert myofibroblast CAFs to a quiescent state, but whether ARBs can reprogram CAFs to promote T lymphocyte activity and enhance immunotherapy is unknown. Moreover, ARB doses are limited by systemic adverse effects such as hypotension due to the importance of angiotensin signaling outside tumors. To enhance the efficacy and specificity of ARBs in cancer with the goal of revealing their effects on antitumor immunity, we developed ARB nanoconjugates that preferentially accumulate and act in tumors. We created a diverse library of hundreds of acid-degradable polymers and chemically linked ARBs to the polymer most sensitive to tumor pH. These tumor microenvironment-activated ARBs (TMA-ARBs) remain intact and inactive in circulation while achieving high concentrations in tumors, wherein they break down to active ARBs. This tumor-preferential activity enhances the CAF-reprogramming effects of ARBs while eliminating blood pressure-lowering effects. Notably, TMA-ARBs alleviate immunosuppression and improve T lymphocyte activity, enabling dramatically improved responses to immune-checkpoint blockers in mice with primary as well as metastatic breast cancer.

23 May 2024 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
MWMichelle W. Wu
Michelle W. Wu
NKNazim Kourdougli
Nazim Kourdougli
CPCarlos Portera-Cailliau
Carlos Portera-Cailliau

9 September 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ICIvy X. Chen
Ivy X. Chen
KNKathleen Newcomer
Kathleen Newcomer
KPKristen E. Pauken
Kristen E. Pauken
VJVikram R. Juneja
Vikram R. Juneja
KNKamila Naxerova
Kamila Naxerova
RJRakesh K. Jain
Rakesh K. Jain
Significance: Immune checkpoint blockade (ICB) has revolutionized treatment of many cancer types, but the majority of treated patients still do not respond to ICB. There is an urgent need to identify predictive biomarkers of response prior to or shortly after therapy initiation, as well as the underlying mechanisms. Here we utilize a model of bilateral tumor implantations followed by resection and immunotherapy-response assessment to study the tumor microenvironment shortly following treatment, identifying biomarkers for response or resistance at early time points. Our biomarker gene signatures derived from CD8+T cells significantly segregate patients by survival and associate with patient response to ICB. Our findings provide a general approach for studying mechanisms of resistance to ICB and discovering predictive biomarkers of response.

1 February 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JLJennifer Li
Jennifer Li
MWMichelle Wu
Michelle Wu
JCJulia Chu
Julia Chu
RSRyan Sochol
Ryan Sochol
SPShyam Patel
Shyam Patel